Hims & Hers management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Read why HIMS ...

Shares in Hims & Hers Health soared in early-morning trading after it announced a partnership with Wegovy maker Novo Nordisk.

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Hims & Hers Health, Inc. teams up with Novo Nordisk to offer Wegovy at $599/month, slashing costs. Click for why this is a ...

Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Novo Nordisk, the maker of Wegovy, announced exclusively on " Good Morning America " Tuesday that the medication will soon be ...